Technical Data
E9005-08H
Exodus 2, Recombinant, Human (SLC, Secondary Lymphoid-tissue Chemokine, 6Ckine, TCA4)
5ug
20ug
Molecular Biology Storage: -20CShipping: Blue Ice
SLC/CCL21, normally expressed in high endothelial venules and in T cell zones of spleen and lymph nodes, strongly attracts T cells and dendritic cells (DC). Secondary lymphoid tissue chemokine (CCL21/SLC) regulates the homing of naive T cells and dendritic cells that express CC-chemokine receptor 7 (CCR7) from distant sites to lymphoid tissue such as lymph nodes.

Description:
Recombinant Human Exodus-2 is also known as SLC (Secondary Lymphoid-Tissue Chemokine), TCA-4 (T-cell activation-4) , and 6Ckine. Recombinant CCL21 produced in E.Coli as a single, non-glycosylated, polypeptide chain containing 111 amino acids and having a molecular mass of 12219 Dalton. Recombinant CCL-21 is purified by proprietary chromatographic techniques.

Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be, Ser-Asp-Gly-Gly-Ala.

Dimers and Aggregates:
Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
Recombinant Human Exodus-2 is fully biologically active when compared to standard. The activity is determined by the chemoattract of human PBE (peripheral blood eosinophils) at a concentration between 0.1-10ng/ml.

Endotoxin:
0.1ng/ug (IEU/ug) of Exodus-2.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm.
2. Analysis by RP-HPLC, using a calibrated solution of Exodus-2 as a Reference Standard.

Solubility:
It is recommended to reconstitute the lyophilized Exodus-2 in sterile 18M -cm H2O not less than 100g/ml, which can then be further diluted to other aqueous solutions.

Stability:
Lyophilized Exodus-2 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Exodus-2 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Molecular Weight:
12.22kD
Source: E. coli
Purity: 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder without additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model. J Allergy Clin Immunol 2006 May;117(5):1040-6. 2. Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol 2006 May 1;176(9):5486-93. 3. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006 Mar 15;66(6):3205-13. 4. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci 2005 Dec;96(12):889-96. 5. Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J Immunol 2005 Oct 15;175(8):4904-13. 6. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006 Jan;13(1):194-202.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.